Top Tweets for #AMPLIA
Amplia Therapeutics CEO Chris Burns has shared his reflections from ASCO, where progress in kRAS inhibition was a major focus in pancreatic cancer. Read the full CEO update: https://t.co/0ixfuvsIkW
$ATX #Amplia #kRAS #pancreaticcancer #oncology #biotech #innovation
#Amplia has announced a new Phase 2b trial of narmafotinib in advanced pancreatic cancer. The study will explore daily dosing of narmafotinib + gemcitabine/Abraxane®, supporting the next stage toward registration. Read the ASX announcement: https://t.co/ZOOjN7310n
A fascinating New York Times feature explores the emerging science of the interstitium and how tumour cells may move through connective tissue networks. The article includes a mention of #Amplia’s lead drug candidate, narmafotinib. https://t.co/H1NrH4j6px
Amplia has announced a new clinical collaboration with @anzgog to evaluate narmafotinib in ovarian cancer. Read the ASX announcement: https://t.co/iXqhg1mU8X $ATX #Amplia #ovariancancer #drugdevelopment #biotech #pharma #oncology #innovation #WOCD2026 #WorldOvarianCancerDay
Amplia Therapeutics has today released its Quarterly Activities and Appendix 4C Cash Flow Report for the quarter ending 31 March 2026. Read the ASX announcement: https://t.co/Ay7w9SKIWn
$ATX #Amplia #ASX #Biotech #Oncology #ClinicalTrials #DrugDevelopment #Innovation
Amplia CEO Dr Chris Burns recently joined Andrew Musgrave on the ASX Briefs Podcast to discuss the Company’s clinical progress and evolving strategy in pancreatic cancer. Have a listen: https://t.co/8cSNZ12KnB $ATX #Amplia #oncology #pancreaticcancer #clinicaltrial #innovation
#Amplia will present mature ACCENT Phase 2a data in metastatic #pancreaticcancer at the AACR Annual Meeting in San Diego today, highlighting promising efficacy and survival outcomes for narmafotinib plus standard chemotherapy. Read the announcement: https://t.co/nM8IfOEL7U
COE amplia a 22 las provincias en alerta por vaguada y frente frontal
Más detalles en: https://t.co/GKPnPviZuf
#COE #Provincias #vaguada #frentefrontal #amplia
Amplia CEO and MD, Dr Chris Burns, will be presenting at 1pm AEDT today at the Ausbiz Capital Investor Connect: Biotech & Pharmaceuticals. Register for free: https://t.co/auiHAG7S7Q $ATX #Amplia #clinicaltrials #pancreaticcancer #innovation #biotech
#Amplia was recently highlighted by Bulls N' Bears as part of its “ASX Runners of the Week” feature in The Age, reflecting strong market interest following the Company’s latest update from the ACCENT trial. Take a look: https://t.co/4YnrqvXk71
#ElInformanteEstadoDeMéxico
#Portada| @UAEM_MX PRESENTA EL #PLANRECTOR DE #DESARROLLOINSTITUCIONAL 2025-2029
Construido de manera #amplia y #participativa, se estructura en seis pilares.
Tags: @PatyzarzaUaemex @Editor_UAEMex @sintesisuaemex
https://t.co/osiDJczjcN
Amplia has announced that two sites in the US have been initiated and will shortly be commencing recruitment activities for the AMPLICITY trial. Read the ASX release: https://t.co/zHvU5LYLps
#ATX #Amplia #pharma #pancreaticcancer #clinicaltrial
Behind every clinical trial is a person living with a diagnosis. On #WorldCancerDay, we thank the patients, families and clinicians who make clinical research possible and who help drive progress toward better treatment options.
$ATX #Amplia #pancreaticcancer #clinicaltrials
Amplia has released its quarterly report for the period ending 31 December 2025, marking significant advancements across the Company’s clinical, commercial and regulatory programs.
Read the report: https://t.co/iCznVJmaPd
$ATX #Amplia #clinicaltrial #pancreaticcancer
$ATX #Amplia has announced the successful completion its first large-scale manufacturing campaign of narmafotinib, producing approximately 13 kg of active pharmaceutical ingredient (API) to the required purity and quality standards.
Read the ASX release: https://t.co/yp9D6tbO2c
Interim data from Amplia’s Phase 2a ACCENT trial in metastatic pancreatic cancer has been presented at the 2026 ASCO Gastrointestinal Cancer Symposium in San Francisco.
Read the ASX release: https://t.co/04LDPylW12
$ATX #Amplia #pancreaticcancer #clinicaltrial #GI26
#Amplia has extended its preclinical research collaboration with Korean drug screening specialist Next&Bio, following a successful initial phase of work and promising preliminary data from the study. Read the ASX release: https://t.co/eWWHTKSqw9
$ATX #FAK #kRAS #pancreaticcancer
Last week, #Amplia CEO Dr Chris Burns FAHMS participated in the Bell Potter Healthcare Conference, joining Healthcare Analyst Thomas Wakim for an in-depth discussion on the Company's clinical development of narmafotinib in #pancreaticcancer.
Take a look: https://t.co/j0FrgQWW0u
Amplia Therapeutics U.S. has begun trading on the U.S. OTCQB Venture Market under the code INNMF effective 29 October.
Read the ASX release: https://t.co/cvueR8Ep9b
$ATX #Amplia #pancreaticcancer #clinicaltrials #OTCQB #innovation #biotech
Most Popular Users
Elon Musk 
@elonmusk
240.7M followers
Barack Obama
@barackobama
119.2M followers
Donald J. Trump
@realdonaldtrump
111.7M followers
Cristiano Ronaldo
@cristiano
110.7M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
97.7M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
90.9M followers
KATY PERRY
@katyperry
87.7M followers
Taylor Swift
@taylorswift13
81.6M followers
Lady Gaga
@ladygaga
73.1M followers
Virat Kohli
@imvkohli
70M followers
Kim Kardashian
@kimkardashian
69.8M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
63.9M followers
Neymar Jr
@neymarjr
62.8M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.9M followers
X
@x
60.8M followers
Selena Gomez
@selenagomez
60.8M followers